BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2018

Publisher Name :
Date: 17-Jul-2018
No. of pages: 129

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2018

Summary

According to the recently published report 'BDNF NT 3 Growth Factors Receptor - Pipeline Review, H2 2018'; BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) pipeline Target constitutes close to 21 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - BDNF/NT-3 growth factors receptor is a protein encoded by the NTRK2 gene. It is involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. It acts as receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. It alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation.

The report 'BDNF NT 3 Growth Factors Receptor - Pipeline Review, H2 2018' outlays comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 7 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Oncology, Genetic Disorders, Cardiovascular, Ear Nose Throat Disorders, Metabolic Disorders and Ophthalmology which include indications Alzheimer's Disease, Solid Tumor, Non-Small Cell Lung Cancer, Breast Cancer, Amyotrophic Lateral Sclerosis, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Colorectal Cancer, Fibrosarcoma, Gastrointestinal Stromal Tumor (GIST), Huntington Disease, Metastatic Colorectal Cancer, Multiple Sclerosis, Neuroblastoma, Parkinson's Disease, Renal Cell Carcinoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Thyroid Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Biliary Tumor, Bladder Cancer, Brain Tumor, Cancer Pain, Carcinoid Tumor, Cervical Cancer, Charcot-Marie-Tooth Disease, Depression, Diabetic Retinopathy, Endometrial Cancer, Epilepsy, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioma, Head And Neck Cancer, Hearing Disorders, Hepatocellular Carcinoma, Ischemic Optic Neuropathy, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Major Depressive Disorder, Melanoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Neurology, Non-Hodgkin Lymphoma, Non-Rhabdomyosarcoma, Non-Small Cell Lung Carcinoma, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Paraganglioma (Glomus Jugulare Tumor), Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rett Syndrome, Rhabdomyosarcoma, Sarcomas, Stroke, Synovial Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Traumatic Brain Injury, Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor (Nephroblastoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)

- The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Overview
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
AstraZeneca Plc
Boehringer Ingelheim GmbH
Celon Pharma SA
Chronos Therapeutics Ltd
Daiichi Sankyo Co Ltd
Exelixis Inc
Handok Inc
Ignyta Inc
Loxo Oncology Inc
MimeTech Srl
Otonomy Inc
Plexxikon Inc
Takeda Pharmaceutical Co Ltd
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Drug Profiles
ACD-855 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Agonize TrKB for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-7451 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNN-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22B10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTO-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-7486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0131304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize NTRK2 for Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize TrkA and TrkB for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize TRKB for Neurodegenrative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize TrkB for CNS Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Dormant Products
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Discontinued Products
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jul 04, 2018: Ipsen reports positive results from CELESTIAL trial for HCC
Jun 04, 2018: NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies
Jun 03, 2018: Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018
Jun 01, 2018: Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metastatic Solid Tumors
May 29, 2018: Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX (cabozantinib) in previously Treated Advanced Hepatocellular Carcinoma
May 29, 2018: Ipsen Announces Clinical Data on Cabometyx to Be Presented at ASCO Demonstrating Its Commitment to Patients with Cancer
May 29, 2018: U.S. FDA accepts larotrectinib New Drug Application and grants priority review
May 17, 2018: European Commission approves Ipsen's Cabometyx (cabozantinib) for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma
May 17, 2018: Bayer Provides Update on larotrectinib at ASCO 2018
Apr 26, 2018: Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting
Mar 28, 2018: Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx, for patients with previously treated advanced Hepatocellular Carcinoma (HCC)
Mar 26, 2018: Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer
Mar 23, 2018: Exelixis Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Mar 15, 2018: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
Feb 21, 2018: Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..4), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Addex Therapeutics Ltd, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Celon Pharma SA, H2 2018
Pipeline by Chronos Therapeutics Ltd, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Exelixis Inc, H2 2018
Pipeline by Handok Inc, H2 2018
Pipeline by Ignyta Inc, H2 2018
Pipeline by Loxo Oncology Inc, H2 2018
Pipeline by MimeTech Srl, H2 2018
Pipeline by Otonomy Inc, H2 2018
Pipeline by Plexxikon Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Vitamin K Antagonists (VKA) Market Insights, Forecast to 2025
    Published: 21-Nov-2018        Price: US 3900 Onwards        Pages: 119
    Vitamin K is a kind of substance with biological activity of leaf green quinone. Rising demand from Asia-Pacific region a major driver for the growth of the market. In 2017, the global Vitamin K Antagonists (VKA) market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Vitamin K Antagonists (VKA) market based on company, product type, application and ......
  • Global Roxatidine Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Nov-2018        Price: US 3480 Onwards        Pages: 123
    Roxatidine is a special H2-receptor antagonist, which is mostly prescribed for reflux esophagitis, benign gastric ulcer, duodenal ulcer, and prophylaxis of recurrent ulcers. It is generally classified as an antacid, anti-reflux, or anti-ulcerant drug. Scope of the Report: The worldwide market for Roxatidine is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Inf......
  • Global Composite Artificial Skin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Nov-2018        Price: US 3480 Onwards        Pages: 122
    Artificial skin are generally prepared from collagen which is easily resorbed by body helps to generate the new skin on the affected part. Continuous research are carried out by various companies to develop new technology in the artificial skin regeneration, such as autologous spray on skin by Avita Medical. Scope of the Report: The worldwide market for Composite Artificial Skin is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$......
  • Global Temporary Artificial Skin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Nov-2018        Price: US 3480 Onwards        Pages: 119
    Artificial skin are generally prepared from collagen which is easily resorbed by body helps to generate the new skin on the affected part. Continuous research are carried out by various companies to develop new technology in the artificial skin regeneration, such as autologous spray on skin by Avita Medical. Scope of the Report: The worldwide market for Temporary Artificial Skin is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$......
  • Global Regenerative Artificial Skin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Nov-2018        Price: US 3480 Onwards        Pages: 124
    Artificial skin are generally prepared from collagen which is easily resorbed by body helps to generate the new skin on the affected part. Continuous research are carried out by various companies to develop new technology in the artificial skin regeneration, such as autologous spray on skin by Avita Medical. Scope of the Report: The worldwide market for Regenerative Artificial Skin is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million ......
  • Global Recording Chart Paper Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Nov-2018        Price: US 3480 Onwards        Pages: 122
    Recording chart paper is a thermal coated special paper used in diagnosis of various healthcare diagnostic procedures with equipment such as ECG monitoring, fetal monitoring, and video image printers. Scope of the Report: The worldwide market for Recording Chart Paper is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report f......
  • Global Pulmonary Dilation Balloon Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Nov-2018        Price: US 3480 Onwards        Pages: 104
    The pulmonary dilation balloon is a technique used in the treatment of pulmonary valve stenosis. Pulmonary valve stenosis is an abnormality in which there is some deformity on or in the vicinity of the pulmonary valve, and this abnormality slows the blood flow. Scope of the Report: The worldwide market for Pulmonary Dilation Balloon is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, accordi......
  • Global Protein Crystallization & Crystallography Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Nov-2018        Price: US 3480 Onwards        Pages: 124
    Proteins are the organic macromolecules that are composed of long chain of amino acids. Protein crystallization and crystallography is the process for the formation of small protein crystals. This process is widely used by industrial and scientific purposes. Proteins normally functions in aqueous environments thus protein crystallization process is generally carried out in water. The main goal behind protein crystallization and crystallography is to develop well ordered protein crystals that ove......
  • Global Bronchitis Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Nov-2018        Price: US 3480 Onwards        Pages: 118
    Bronchitis is inflammation of the bronchi (large and medium-sized airways) in the lungs. Symptoms include coughing up mucus, wheezing, shortness of breath, and chest discomfort. Bronchitis is divided into two types: acute and chronic. Acute bronchitis is also known as a chest cold. Scope of the Report: The worldwide market for Bronchitis is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, acc......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs